Back to Search
Start Over
Patterns of Erythropoiesis-Stimulating Agent Use in European Hemodialysis Patients: The Dialysis Outcomes and Practice Patterns Study
Patterns of Erythropoiesis-Stimulating Agent Use in European Hemodialysis Patients: The Dialysis Outcomes and Practice Patterns Study
- Source :
- Nephron. 140(1)
- Publication Year :
- 2018
-
Abstract
- Background: Clinicians providing dialysis care have numerous erythropoiesis-stimulating agents (ESAs) available for treating anemia. We sought to provide a contemporary description of ESA types used in hemodialysis (HD) settings in nine European countries. Methods: Our study uses Dialysis Outcomes and Practice Patterns Study phase 5 (2012–2015) data from nine European countries (Belgium, France, ­Germany, Italy, Russia, Spain, Sweden, Turkey, and the United Kingdom). A total of 164 facilities and 3,281 patients contributed cross-sectional data. ESA types captured included short-acting epoetins (e.g., epoetin alfa, beta, etc., including biosimilars), darbepoetin alfa, and continuous erythropoietin receptor agonist (CERA; methoxy polyethylene glycol-epoetin beta). Results: We observed broad variability across countries in prescription of ESA types: prescription of epoetin alfa or epoetin beta ranged from 22% (France) to 78% (Russia), darbepoetin alfa prescription ranged from 13% (Russia) to 53% (UK), and CERA prescription ranged from Conclusion: A variety of short- and long-acting ESAs are commonly used in European HD facilities to maintain hemoglobin at remarkably similar levels with each ESA type. The availability of numerous ESA options for managing anemia has allowed European providers to optimize anemia management according to the particular circumstances of each patient.
- Subjects :
- 030213 general clinical medicine
medicine.medical_specialty
Darbepoetin alfa
medicine.drug_class
Anemia
medicine.medical_treatment
030232 urology & nephrology
Cohort Studies
03 medical and health sciences
Hemoglobins
0302 clinical medicine
Renal Dialysis
hemic and lymphatic diseases
medicine
Receptors, Erythropoietin
Humans
Prospective Studies
Medical prescription
Practice Patterns, Physicians'
Biosimilar Pharmaceuticals
Erythropoietin
Dialysis
Epoetin beta
business.industry
Epoetin alfa
Erythropoiesis-stimulating agent
medicine.disease
Europe
Cross-Sectional Studies
Treatment Outcome
Emergency medicine
Hematinics
Kidney Failure, Chronic
Hemodialysis
business
medicine.drug
Subjects
Details
- ISSN :
- 22353186
- Volume :
- 140
- Issue :
- 1
- Database :
- OpenAIRE
- Journal :
- Nephron
- Accession number :
- edsair.doi.dedup.....b07647e3be67d0635bddb97d5fc17fc3